Business
Forlong Bio secures USD 17.5m in Pre-B funding for cytokine pipeline advancement
Suzhou-based Forlong Biotechnology has closed a Series Pre-B financing round of approximately RMB 120 million (USD 17.5 million) to advance its IL-15 and...
Incyte partners with Edison Scientific to deploy Kosmos agentic AI platform across drug discovery
Incyte (Nasdaq: INCY) has entered a collaboration agreement with Edison Scientific, a San Francisco-based AI company founded in 2025, to embed Edison's...
Accro Bioscience closes USD 50 million Series C to advance RIPK2 inhibitor ulcerative colitis
Accro Bioscience closes USD 50 million Series C to advance RIPK2 inhibitor in ulcerative colitis
Gossamer Bio exchanges USD 120m convertible debt to stabilize balance sheet ahead of seralutinib PAH filing
San Diego-based Gossamer Bio (Nasdaq: GOSS) has announced an exchange offer and concurrent consent solicitation targeting more than USD 120 million of its...
Hansa Biopharma licenses Europe, MENA rights for Idefirix to SERB Pharmaceuticals for EUR 115m
Hansa Biopharma (Nasdaq Stockholm: HNSA), the Lund, Sweden-based biopharmaceutical company, has licensed European and MENA commercialization rights for...
Quince acquires Orphai for inhaled mTOR inhibitor, raises USD 187m
Quince Therapeutics (Nasdaq: QNCX), based in South San Francisco, has acquired Orphai Therapeutics Inc., a private clinical-stage company, in a...
Merck partners with China's Degron, Medimscience on molecular glue, autoimmune programs
Merck (NYSE: MRK) has signed two clinical collaboration agreements and two memorandums of understanding with Chinese biotech companies through its MSD R&D...
Context Therapeutics pays USD 6.5m to buy out BioAtla CT-202 Nectin-4 CD3 obligations
Context Therapeutics (Nasdaq: CNTX) has paid USD 6.5 million to buy out all future milestone and royalty obligations on CT-202, its Nectin-4 x CD3 T cell...
Neurocrine completes USD 2.9b acquisition of Soleno for rare disease portfolio expansion
Neurocrine Biosciences (Nasdaq: NBIX) has completed its acquisition of Soleno Therapeutics for a total equity value of USD 2.9 billion, adding VYKAT XR...
Regeneron and Parabilis strike USD 2.325b deal for antibody-Helicon conjugate therapeutics
Regeneron Pharmaceuticals (Nasdaq: REGN) has entered a research collaboration with private Cambridge, Massachusetts-based Parabilis Medicines to discover...
Allogene terminates CAR-T deal with Overland Therapeutics, reclaims global rights
Allogene Therapeutics (Nasdaq: ALLO) has terminated its five-year regional licensing agreement with Overland Therapeutics, reclaiming full global rights to...
Mirum Pharma issues USD 600m convertible notes to refinance 2029 debt, fund rare disease acquisitions
Foster City, California-based Mirum Pharmaceuticals (Nasdaq: MIRM) has announced the pricing of USD 600 million in aggregate principal of 0.00% convertible...
Gilead fills acquisitions war chest with USD 3b senior note offering
Gilead Sciences (Nasdaq: GILD) has announced the pricing of USD 3 billion in senior unsecured notes across four tranches in an underwritten registered...
CapeHaven completes first close toward USD 10 million seed funding for Yale biotech spinouts
CapeHaven launches Yale biotech spinout vehicle with USD 10 million target
Biogen completes USD 3.2b acquisition of Apellis Pharma for complement inhibitor assets
Biogen (Nasdaq: BIIB) has completed its acquisition of Apellis Pharmaceuticals, adding two commercially approved complement inhibitors and an established...
The AllSci Brief
Systematic R&D and deal news. Daily.